{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:42:05Z","timestamp":1792730525085,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejim.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:40:08Z","timestamp":1753299608000},"page":"106420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-3120","authenticated-orcid":false,"given":"Claudia","family":"St\u00f6llberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Finsterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birke","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0001","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/dom.15472","article-title":"Use of sodium-glucose cotransporter-2 inhibitors in France: analysis of French nationwide health insurance database","volume":"26","author":"de Germay","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.016_bib0002","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized Clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.016_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100765","article-title":"Myopathy associated with statins and SGLT2 - A review of literature","volume":"46","author":"Gupta","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.016_bib0004","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1007\/s10072-022-06046-3","article-title":"A case of anti-HMGCR myopathy triggered by sodium\/glucose co-transporter 2 (SGLT2) inhibitors","volume":"43","author":"Stella","year":"2022","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0005","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.13137","article-title":"Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report","volume":"11","author":"Yasuda","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.016_bib0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/jpm14020141","article-title":"The safety and efficacy of sodium-glucose cotransporter-2 inhibitors for patients with sarcopenia or frailty: double edged sword?","volume":"14","author":"Naito","year":"2024","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcsm.12048","article-title":"SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes","volume":"7","author":"Malmstrom","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41387-022-00223-1","article-title":"Validation of a multi-frequency bioelectrical impedance analysis device for the assessment of body composition in older adults with type 2 diabetes","volume":"12","author":"Buch","year":"2022","journal-title":"Nutr Diabetes"},{"issue":"9\u201310","key":"10.1016\/j.ejim.2025.07.016_bib0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s12272-021-01349-z","article-title":"Understanding of sarcopenia: from definition to therapeutic strategies","volume":"44","author":"Kim","year":"2021","journal-title":"Arch Pharm Res"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0011","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17425255.2021.1921735","article-title":"Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence","volume":"17","author":"Lalagkas","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a controversy that must be solved","volume":"42","author":"Afsar","year":"2023","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.016_bib0013","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.16093","article-title":"Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs","volume":"12","author":"Newsom","year":"2024","journal-title":"Physiol Rep"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0014","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s13300-023-01481-7","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review","volume":"14","author":"Jahangiri","year":"2023","journal-title":"Diabetes Ther"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2025.07.016_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1220516","article-title":"Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Xia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejim.2025.07.016_bib0017","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0018","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/clc.23970","article-title":"Prevalence of sarcopenia and its association with clinical outcomes in heart failure: an updated meta-analysis and systematic review","volume":"46","author":"Chen","year":"2023","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0019","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jgs.18227","article-title":"Limited physician knowledge of sarcopenia: a survey","volume":"71","author":"Guralnik","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12874-024-02292-5","article-title":"Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.Gov: a cross-sectional study","volume":"24","author":"\u0160aler","year":"2024","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.016_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43425","article-title":"Industry involvement and transparency in the most cited clinical trials, 2019-2022","volume":"6","author":"Siena","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"37","key":"10.1016\/j.ejim.2025.07.016_bib0022","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0023","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0024","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s13300-021-01047-5","article-title":"Effects of sodium glucose Co-transporter 2 inhibitors in type 1 diabetes mellitus on body composition and glucose variabilities: single-arm, exploratory trial","volume":"12","author":"Baba","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1507\/endocrj.EJ20-0599","article-title":"Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial","volume":"68","author":"Bouchi","year":"2021","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jcsm.13393","article-title":"Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-preserved","volume":"15","author":"Coats","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.016_bib0028","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1530\/EC-20-0082","article-title":"Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use","volume":"9","author":"Goto","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ejim.2025.07.016_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109781","article-title":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial","volume":"186","author":"Horibe","year":"2022","journal-title":"Diabetes Res Clin Pr"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/jcm13061670","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure with malnutrition, frailty, sarcopenia, or cachexia","volume":"13","author":"Horiuchi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2025.07.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6470137","article-title":"Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus","author":"Kamei","year":"2018","journal-title":"J Diabetes Res"},{"issue":"19","key":"10.1016\/j.ejim.2025.07.016_bib0032","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.3390\/jcm11195956","article-title":"Association between SGLT2 inhibitors and cardiac rehabilitation outcomes in patients with cardiovascular disease and type 2 diabetes mellitus","volume":"11","author":"Kashima","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0033","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13340-017-0307-1","article-title":"Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin","volume":"8","author":"Kato","year":"2017","journal-title":"Diabetol Int"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0034","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0035","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/dom.14508","article-title":"Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes","volume":"23","author":"Matsuba","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.016_bib0036","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of Dapagliflozin versus Placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.016_bib0037","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14740\/jocmr3785","article-title":"Differing effect of the sodium-glucose cotransporter 2 inhibitor Ipragliflozin on the decrease of fat mass vs. Lean mass in patients with or without metformin therapy","volume":"11","author":"Nagai","year":"2019","journal-title":"J Clin Med Res"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0038","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1210\/jc.2018-01741","article-title":"Influence of sodium glucose cotransporter 2 inhibition on physiological adaptation to endurance exercise training","volume":"104","author":"Newman","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"10.1016\/j.ejim.2025.07.016_bib0039","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of Canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.ejim.2025.07.016_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","author":"Op den Kamp","year":"2022","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.016_bib0041","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/nu12020510","article-title":"Sodium glucose Co-transporter 2 inhibition does not favorably modify the physiological responses to dietary counselling in diabetes-free, sedentary overweight and obese adult humans","volume":"12","author":"Ryan","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13340-021-00512-7","article-title":"Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes","volume":"13","author":"Sakamoto","year":"2021","journal-title":"Diabetol Int"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0043","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"6","key":"10.1016\/j.ejim.2025.07.016_bib0044","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ejim.2025.07.016_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0046","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bcpt.13991","article-title":"Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes","volume":"134","author":"Voigt","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90879-z","article-title":"A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin","volume":"11","author":"Watanabe","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2025.07.016_bib0048","article-title":"Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction","author":"Wood","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0049","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/jdi.13179","article-title":"Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial","volume":"11","author":"Yamakage","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.016_bib0051","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jdi.14054","article-title":"Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type\u20091 diabetes mellitus","volume":"14","author":"Yoshimura","year":"2023","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0052","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21486-9","article-title":"Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin","volume":"12","author":"Zeng","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0053","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1007\/s10067-024-07206-w","article-title":"Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study","volume":"43","author":"Oakes","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"22","key":"10.1016\/j.ejim.2025.07.016_bib0054","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.3390\/nu16223841","article-title":"Sodium-glucose cotransporter 2 inhibitors improve body composition by increasing the skeletal muscle mass\/fat mass ratio in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"16","author":"Volpe","year":"2024","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0055","first-page":"2096","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on body composition and fluid status in cardiovascular rehabilitation patients with coronary artery disease and heart failure","volume":"60","author":"De La Flor","year":"2024","journal-title":"Med (Kaunas)"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.016_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.46641","article-title":"Rhabdomyolysis and sodium-glucose-linked transport inhibitors in patients taking statins","volume":"7","author":"Harel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.016_bib0057","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0549","article-title":"Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report","volume":"173","author":"Brailovski","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2025.07.016_bib0058","article-title":"Myopathy secondary to empagliflozin therapy in type 2 diabetes","volume":"2020","author":"Gao","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BJMMR\/2017\/33253","article-title":"Marked weight loss, muscle wasting and fatigue on administration of empagliflozin in a subject with type 2 diabetes","volume":"21","author":"Kabadi","year":"2017","journal-title":"Br J Med Med Res"},{"issue":"10","key":"10.1016\/j.ejim.2025.07.016_bib0060","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.3390\/jcm13102828","article-title":"Unexpectedly rapid onset of severe sarcopenia in an elderly diabetic man following SGLT2i administration: a case report","volume":"13","author":"Czarnecka","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0061","doi-asserted-by":"crossref","first-page":"luae216","DOI":"10.1210\/jcemcr\/luae216","article-title":"Empagliflozin-induced myopathy","volume":"2","author":"Khan","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0062","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40264-022-01166-3","article-title":"Drug-Drug interaction of the sodium glucose Co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data","volume":"45","author":"Alkabbani","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejim.2025.07.016_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15711","article-title":"Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis","author":"Gravel","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2025.07.016_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105656","article-title":"Worldwide burden of antidiabetic drug-induced sarcopenia: an international pharmacovigilance study","volume":"129","author":"Kong","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.ejim.2025.07.016_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2412234","article-title":"Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study","author":"Kuai","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.ejim.2025.07.016_bib0066","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ejhf.3441","article-title":"Letter regarding the article 'Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction","volume":"26","author":"St\u00f6llberger","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.ejim.2025.07.016_bib0067","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2018.08.2182","article-title":"Cardiac Phenotypes in hereditary muscle disorders: JACC State-of-the-art review","volume":"72","author":"Arbustini","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ejim.2025.07.016_bib0068","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejim.2025.07.016_bib0069","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejim.2025.07.016_bib0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.07.016_bib0071","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2025.07.016_bib0072","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.15780","article-title":"Spotlight commentary: the value of spontaneous reporting systems to detect (the lack of) clinically relevant drug-drug interactions in clinical practice","volume":"89","author":"Raschi","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ejim.2025.07.016_bib0073","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.9778\/cmajo.20220039","article-title":"Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease","volume":"11","author":"Ozaki","year":"2023","journal-title":"CMAJ Open"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.016_bib0074","doi-asserted-by":"crossref","first-page":"273","DOI":"10.31083\/j.rcm2409273","article-title":"Sarcopenia predicts adverse prognosis in patients with heart failure: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2023","journal-title":"Rev Cardiovasc Med"},{"issue":"10431","key":"10.1016\/j.ejim.2025.07.016_bib0075","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.016_bib0076","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.ejim.2025.07.016_bib0077","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejim.2025.07.016_bib0078","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.07.016_bib0079","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2025.07.016_bib0080","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/jcm9051603","article-title":"Sodium-glucose cotransporter 2 inhibitors and kidney outcomes: true renoprotection, loss of muscle mass or both?","volume":"9","author":"Post","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.07.016_bib0081","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/jcsm.12969","article-title":"Muscle mass and estimates of renal function: a longitudinal cohort study","volume":"13","author":"Groothof","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"10.1016\/j.ejim.2025.07.016_bib0082","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfad083","article-title":"Estimation of glomerular filtration rate in cardiorenal patients: a step forward","volume":"16","author":"Quiroga","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.ejim.2025.07.016_bib0083","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14659","article-title":"Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors","volume":"39","author":"Choosongsang","year":"2022","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.ejim.2025.07.016_bib0084","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/cvr\/cvae073","article-title":"Biological basis and treatment of frailty and sarcopenia","volume":"120","author":"Sato","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:01:28Z","timestamp":1762207288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525002985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":84,"alternative-id":["S0953620525002985"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106420"}}